These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28514405)

  • 21. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.
    Venetsanopoulou AI; Voulgari PV; Alamanos Y; Papadopoulos CG; Markatseli TE; Drosos AA
    Rheumatol Int; 2007 Aug; 27(10):935-9. PubMed ID: 17357804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells.
    Schramm-Luc A; Schramm J; Siedliński M; Guzik TJ; Batko B
    Clin Rheumatol; 2018 Jun; 37(6):1597-1604. PubMed ID: 29546695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.
    Gentileschi S; Vitale A; Rigante D; Lopalco G; Emmi G; Orlando I; Di Scala G; Sota J; Fabiani C; Frediani B; Galeazzi M; Lapadula G; Iannone F; Cantarini L
    Isr Med Assoc J; 2018 Jul; 20(7):438-441. PubMed ID: 30109794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.
    Milanez FM; Saad CG; Viana VT; Moraes JC; Périco GV; Sampaio-Barros PD; Goncalves CR; Bonfá E
    Arthritis Res Ther; 2016 Feb; 18():52. PubMed ID: 26912133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
    van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
    Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.
    Lorenzin M; Ortolan A; Frallonardo P; Oliviero F; Punzi L; Ramonda R
    BMC Musculoskelet Disord; 2015 Jul; 16():166. PubMed ID: 26205000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study.
    Pan JE; Xiong FL; Chen G; Zhang ZW; Xu YJ
    Biomed Pharmacother; 2017 Nov; 95():1549-1555. PubMed ID: 28950654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis.
    Ozgocmen S; Godekmerdan A; Ozkurt-Zengin F
    Joint Bone Spine; 2007 May; 74(3):249-53. PubMed ID: 17387033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
    Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical significance of high sensitivity C-reactive protein for evaluating the efficacy of etanercept in active ankylosing spondylitis].
    Zhang J; Huang F; Zhang J; Deng X; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(3):204-7. PubMed ID: 24731464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis.
    Park MC; Lee SW; Choi ST; Park YB; Lee SK
    Scand J Rheumatol; 2007; 36(2):101-6. PubMed ID: 17476615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.